Neogenomics (NEO) Cost of Revenue (2010 - 2026)

Neogenomics has reported Cost of Revenue for 17 years, with the latest figure at $105.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 366.46% year-over-year to $105.8 million; the trailing twelve-month figure through Mar 2026 stood at $260.7 million (down 49.46% YoY), and the FY2025 full-year result was $92.0 million, down 75.16% from the prior year.
• Cost of Revenue for Q1 2026 stood at $105.8 million, up from $23.4 million in the prior quarter.
• The five-year high for Cost of Revenue was $308.2 million in Q4 2024, with the low at -$188.2 million in Q4 2023.
• Historically, Cost of Revenue has averaged $55.0 million across 5 years, with a median of $24.1 million in 2025.
• Annual changes were most pronounced in 2023 — Cost of Revenue tumbled 1198.08% — and 2024, when it jumped 458.28%.
• Neogenomics' Cost of Revenue stood at $17.1 million in 2022, then plunged by 1198.08% to -$188.2 million in 2023, then surged by 263.71% to $308.2 million in 2024, then slumped by 92.39% to $23.4 million in 2025, then soared by 351.34% to $105.8 million in 2026.
• The last three Cost of Revenue figures came in at $105.8 million (Q1 2026), $23.4 million (Q4 2025), and $107.4 million (Q3 2025), per Business Quant data.